Opus Genetics is trading at $4.75 (+6.72%) after its September 2 announcement of a September 9 webcast presenting topline Cohort 1 data from the Phase 1/2 OPGx-BEST1 study.
- The company also plans full-data presentations at upcoming ophthalmology conferences, increasing investor focus on potential clinical readouts.
- Shares rose 16.19% on September 2 and 5.80% on September 1, while biotech sentiment is also supportive.